Radotinib clinical trials
Also written IY5511HCl.
How each study uses radotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the radotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Il-Yang Pharm. Co., Ltd. (6) · Ulsan University Hospital (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test radotinib, phase 3 first.
- Jun 2027A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsPhase 3 · Il-Yang Pharm. Co., Ltd.
Studies
Open first, then newest update. How each study uses radotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsRecruitingPhase 3Il-Yang Pharm. Co., Ltd.NCT03459534Written as Radotinib HCl
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingPhase 3Il-Yang Pharm. Co., Ltd.NCT03722420Written as Radotinib
- Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive, not recruitingPhase 2Il-Yang Pharm. Co., Ltd.NCT04691661Written as Radotinib HCl 50 mg
- Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered RadotinibCompletedPhase 1Il-Yang Pharm. Co., Ltd.NCT06461078Written as Radotinib HCl
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedPhase 1/2Il-Yang Pharm. Co., Ltd.NCT01602952Written as Radotinib
- Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknownPhase 2Ulsan University HospitalNCT02422719Written as Radotinib
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedPhase 3Il-Yang Pharm. Co., Ltd.NCT01511289Written as Radotinib
Codes
What other systems call radotinib · ClinicalTrials.gg INT000436
- UNII (FDA) I284LJY110RADOTINIBConfirmed FDA, Wikidata
- Wikidata Q15269680radotinibConfirmed FDA, Wikidata
- NCI Thesaurus C98110RadotinibOne source FDA
- DrugBank DB12323One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | I284LJY110 | RADOTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q15269680 | radotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C98110 | Radotinib | One source FDA |
| DrugBank | DB12323 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.